Disclosed positions
| Trevi Therapeutics Inc | TRVI | Common | $95,015,558 | 5,094,668 | SH | None |
| Praxis Precision Medicines | PRAX | Common | $90,766,926 | 271,116 | SH | None |
| Erasca Inc | ERAS | Common | $75,614,188 | 4,127,412 | SH | None |
| Arrivent BioPharma Inc | AVBP | Common | $58,436,050 | 1,682,097 | SH | None |
| Abivax SA - ADR | ABVX | SPONSORED ADS | $55,289,441 | 414,899 | SH | None |
| Tango Therapeutics Inc | TNGX | Common | $43,131,579 | 1,379,769 | SH | None |
| Corvus Pharmaceuticals Inc | CRVS | Common | $41,918,891 | 2,805,816 | SH | None |
| Bright Minds Biosciences Inc | DRUG | Common | $39,113,474 | 557,172 | SH | None |
| Sinovac Biotech Ltd. | Unresolved | SHS | $38,192,410 | 5,903,000 | SH | None |
| Tenax Therapeutics Inc | TENX | Common | $36,375,000 | 2,500,000 | SH | None |
| Aclaris Therapeutics, Inc. | ACRS | Common | $35,414,630 | 6,694,637 | SH | None |
| Dyne Therapeutics Inc | DYN | Common | $34,591,320 | 1,557,466 | SH | None |
| Dianthus Therapeutics Inc | DNTH | Common | $34,507,725 | 353,998 | SH | None |
| Alto Neuroscience Inc | ANRO | Common | $31,901,763 | 1,208,858 | SH | None |
| DBV Technologies SA | DBVT | SPONSORED ADS | $30,254,031 | 1,844,758 | SH | None |
| SAB Biotherapeutics Inc | SABS | Common | $28,469,645 | 7,299,909 | SH | None |
| Moonlake Immunotherapeutics | MLTX | Class A ORD | $27,258,000 | 1,400,000 | SH | None |
| LB Pharmaceuticals Inc | LBRX | Common | $25,964,000 | 800,000 | SH | None |
| Minerva Neurosciences Inc | NERV | Common | $23,991,246 | 4,322,747 | SH | None |
| Design Therapeutics Inc | DSGN | Common | $23,338,706 | 1,612,903 | SH | None |
| Oric Pharmaceuticals Inc | ORIC | Common | $20,022,352 | 1,848,786 | SH | None |
| CAMP4 Therapeutics Corporation | CAMP | Common | $18,557,502 | 4,246,568 | SH | None |
| Faeth Therapeutics Inc | FTH | Common | $18,050,500 | 722,020 | SH | None |
| Achieve Life Sciences Inc. | ACHV | Common | $17,964,239 | 2,751,032 | SH | None |
| Compass Therapeutics Inc | CMPX | Common | $16,987,961 | 7,757,060 | SH | None |
| AN2 Therapeutics Inc | ANTX | Common | $15,263,618 | 3,153,640 | SH | None |
| Editas Medicine Inc | EDIT | Common | $11,519,010 | 3,555,250 | SH | None |
| Geron Corp | GERN | Common | $11,099,900 | 8,671,797 | SH | None |
| Odyssey Therapeutics Inc | ODTX | Common | $10,758,250 | 575,000 | SH | None |
| Eupraxia Pharmaceuticals Inc | EPRX | Common | $8,923,500 | 1,350,000 | SH | None |
| Onkure Therapeutics Inc | OKUR | Common | $8,790,358 | 1,927,710 | SH | None |
| Olema Pharmaceuticals Inc | OLMA | Common | $8,404,756 | 671,843 | SH | None |
| Monopar Therapeutics Inc | MNPR | Common | $8,379,395 | 90,500 | SH | None |
| Aura Biosciences Inc | AURA | Common | $8,283,336 | 1,166,667 | SH | None |
| Surrozen Inc | SRZN | Common | $6,747,000 | 260,000 | SH | None |
| ALX Oncology Holdings Inc | ALXO | Common | $6,592,356 | 3,184,713 | SH | None |
| Satellos Bioscience Inc | MSLE | Common | $6,326,253 | 813,666 | SH | None |
| Avalo Therapeutics Inc | AVTX | Common | $5,082,000 | 275,000 | SH | None |
| Pepgen Inc | PEPG | Common | $4,185,000 | 2,325,000 | SH | None |
| Valneva SE | VALN | SPONSORED ADS | $3,991,531 | 763,199 | SH | None |
| Sera Prognostics Inc | SERA | Common | $3,003,801 | 1,650,440 | SH | None |
| Unicycive Therapeutics | UNCY | Common | $2,579,500 | 550,000 | SH | None |
| Instil Bio Inc | TIL | Common | $2,251,194 | 292,743 | SH | None |
| InMed Pharmaceuticals Inc | INM | Common | $1,237,484 | 798,377 | SH | None |
| Bolt Biotherapeutics Inc | BOLT | Common | $278,794 | 72,414 | SH | None |
| Pasithea Therapeutics Corp | KTTA | Common | $239,904 | 465,471 | SH | None |
| Precision Biosciences Inc | DTIL | Common | $36,746 | 4,675 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 1 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.